1. Eisai Inc. US veterans’ health administration (VHA) provides coverage of Leqembi (lecanemab-irmb) two months after Leqembi’s FDA accelerated approval for veterans living with early stages of Alzheimer’s disease. (Press release). March 13, 2023. https://www.eisai.com/news/2023/news202319.html
2. Food and Drug Administration. FDA grants accelerated approval for Alzheimer’s disease treatment. January 6, 2023 (press release) https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment
3. Aduhelm: Approval of Alzheimer’s drug was highly unorthodox, finds report
4. Metzger L, Kwong E, Oza A, et al. How well does a new Alzheimer’s drug work for those most at risk? National Public Radio. Short Wave. March 13, 2023. https://www.npr.org/2023/03//10/1162601892/how-well-does-a-new-alzheimers-drug-work-for-those-most-at-risk
5. Veterans Administration. Leqembi-irmb. (LEQEMBI) Criteria for use. February 2023. https://www.va.gov/formularyadvisor/DOC_PDF/CFU_Lecanemab-irmb_LEQEMBI_CFU.pdf www.cnbc.com/2023/03/13.veterans-health-will-cover-alzheimers-treatment